Your browser doesn't support javascript.
loading
Parkinson's Disease: Basic knowledge. / Parkinson-Krankheit: Basiswissen.
Med Monatsschr Pharm ; 39(7): 277-81, 2016 Jul.
Article em En, De | MEDLINE | ID: mdl-29953178
ABSTRACT
Pharmacotherapy in Parkinson's disease is complex and requires expertise in all health-care professions. Besides idiopathic Parkinson's disease (IPD) secondary parkinsonism, monogenetic Parkinson's disease and atypical syndromes need to be differentiated. The prevalence in the European population is estimated to be approximately 1 %. Lifestyle and age are closely linked to IPD. Neurodegeneration with formation of Lewy-bodies and increased oxidative stress in the pars compacta of the substantia nigra are closely linked to IPD. Lewy-bodies show misfolded α-Synuclein. The balance of glutamate, GABA and dopamine is essential for motor complications. Bradykinesia/akinesia, rigidity, rest tremor and postural instability are typical symptoms along with dissymmetry, shuffling gait and camptocormia, micrographia, aphasia, hypophonia, dysphagia, and hypomimia. Early symptoms are akathisia/restlessness, insomnia, somnolence, hyposmia and neck pain. With further progression of IPD, neurons of the ventral tegmental area are affected and lead to non-motor symptoms, which hence are directly related to the underlying disease. Gastric dysmotility, depression, urinary incontinence, excessive sweating, hallucinations, spasticity, muscle pain and Parkinson's disease dementia are part of IPD.
Assuntos
Buscar no Google
Base de dados: MEDLINE Assunto principal: Doença de Parkinson / Antiparkinsonianos Tipo de estudo: Diagnostic_studies / Etiology_studies / Risk_factors_studies Limite: Humans Idioma: De / En Ano de publicação: 2016 Tipo de documento: Article
Buscar no Google
Base de dados: MEDLINE Assunto principal: Doença de Parkinson / Antiparkinsonianos Tipo de estudo: Diagnostic_studies / Etiology_studies / Risk_factors_studies Limite: Humans Idioma: De / En Ano de publicação: 2016 Tipo de documento: Article